Prealbumin-to-Globulin Ratio Can Predict the Chemotherapy Outcomes and Prognosis of Patients with Gastric Cancer Receiving First-Line Chemotherapy

Table 4

Correlations between survival and the PGR and other clinicopathological factors.

	Progression-free survival						Overall survival
	Univariate analysis			Multivariate analysis			Univariate analysis			Multivariate analysis
	Hazard ratio	95% CI	value	Hazard ratio	95% CI	value	Hazard ratio	95% CI	value	Hazard ratio	95% CI	value
Sex (male)	1.073	0.835-1.379	0.582				1.145	0.891-1.471	0.290
Age (>60 years)	0.991	0.781-1.256	0.939				0.797	0.627-1.012	0.062	0.874	0.674-1.133	0.309
Body mass index (<18.5 or >25 kg/m^2)	0.923	0.705-1.207	0.558				1.084	0.828-1.420	0.557
ECOG (≥2)	1.124	0.823-1.535	0.463				1.174	0.859-1.604	0.313
Histological type (poorly cohesive, mucinous)	1.492	1.136-1.959	0.004	1.495	1.137-1.965	0.004	1.537	1.172-2.015	0.002	1.407	1.067-1.855	0.015
TNM stage (IV)	1.206	0.897-1.622	0.214				1.368	1.017-1.839	0.038	1.186	0.855-1.643	0.306
Number of organs affected by metastasis (≥2)	1.390	1.081-1.786	0.010	1.400	1.077-1.818	0.012	1.364	1.058-1.758	0.017	1.294	0.973-1.721	0.077
Peritoneal metastasis (yes)	1.526	1.185-1.966	<0.001	1.297	0.991-1.696	0.058	1.710	1.325-2.205	<0.001	1.426	1.062-1.915	0.018
CEA (>5 ng/mL)	1.222	0.959-1.557	0.105	1.138	0.878-1.474	0.328	1.278	1.004-1.626	0.046	1.299	1.004-1.680	0.046
CA72-4 (>6 U/mL)	1.425	1.118-1.816	0.004	1.411	1.091-1.824	0.009	1.254	0.989-1.590	0.061	1.164	0.903-1.501	0.240
CA19-9 (>37 U/mL)	1.051	0.825-1.339	0.686				1.046	0.821-1.332	0.717
Hemoglobin (<115 g/L)	0.905	0.708-1.157	0.424				0.890	0.697-1.136	0.349
PGR ≥7.21	0.644	0.508-0.817	<0.001	0.672	0.527-0.857	0.001	0.644	0.507-0.817	<0.001	0.675	0.530-0.861	0.002

ECOG: Eastern Cooperative Oncology Group; TNM: tumor-node-metastasis; CEA: carcinoembryonic antigen; CA72-4: carbonhydrate antigen 72-4; CA 19-9: carbohydrate antigen 19-9; PGR: prealbumin-to-globulin ratio.